Alzheimer’s disease affects millions of people worldwide and is one of the most difficult conditions to treat. It slowly damages the brain, leading to memory loss and loss of independence. For many years, researchers believed that a protein called amyloid was the main cause of the disease.
Amyloid builds up in the brain and forms plaques, which can be seen in people with Alzheimer’s disease. Because of this, scientists developed drugs to remove amyloid, hoping that this would slow down or stop the disease.
After decades of research, two drugs, lecanemab and donanemab, were introduced and approved in several countries. These drugs were seen as a major step forward.
However, a new review of research has raised concerns about their real benefits. The review was conducted by Cochrane and published in the Cochrane Database of Systematic Reviews. It examined results from 17 clinical trials involving more than 20,000 participants.
All of these studies tested drugs that target amyloid. Most participants had early-stage Alzheimer’s disease or mild cognitive problems. Researchers hoped that treating the disease early would lead to better results.
The findings showed that the drugs were successful in reducing amyloid levels in the brain. However, this did not lead to clear improvements in memory or thinking ability. The changes observed in the studies were very small and unlikely to be noticed in everyday life.
This is an important reminder that changing a biological marker does not always improve a patient’s condition. In this case, removing amyloid did not appear to significantly slow the disease.
The review also found that these drugs can cause side effects. Some patients developed swelling or bleeding in the brain, which can be serious. Even though many of these cases did not cause immediate symptoms, the risks cannot be ignored.
Not everyone agrees with the review’s conclusions. Some experts believe the analysis may not fully reflect the benefits of newer drugs. Others argue that amyloid may still play a role in Alzheimer’s disease, even if current treatments are not effective enough.
Another important point is that Alzheimer’s disease is complex. It may involve many different processes in the brain, not just amyloid buildup. This means that future treatments may need to target multiple pathways instead of focusing on one single factor.
Despite the debate, the review highlights an important issue. The current generation of anti-amyloid drugs may not provide the meaningful improvements that patients and doctors are hoping for. At the same time, the risks and high costs of these treatments need to be carefully considered.
In summary, while these drugs represent years of research and effort, their benefits appear limited so far. This does not mean the amyloid theory is completely wrong, but it suggests that it may not be the whole story. More research is needed to better understand the disease and to develop more effective treatments.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: Cochrane.
